Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Declines By 52.7%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totalling 448,000 shares, a decline of 52.7% from the June 30th total of 947,400 shares. Based on an average trading volume of 4,950,000 shares, the days-to-cover ratio is currently 0.1 days.

Sonoma Pharmaceuticals Price Performance

Shares of Sonoma Pharmaceuticals stock traded down $0.03 during trading on Friday, reaching $0.35. The company’s stock had a trading volume of 719,831 shares, compared to its average volume of 4,188,936. The firm’s 50-day moving average is $0.25 and its two-hundred day moving average is $0.19. Sonoma Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $1.15.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings data on Monday, June 17th. The company reported ($0.07) earnings per share (EPS) for the quarter. Sonoma Pharmaceuticals had a negative net margin of 37.97% and a negative return on equity of 64.15%. The company had revenue of $3.44 million for the quarter. Equities research analysts expect that Sonoma Pharmaceuticals will post -0.2 EPS for the current year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.